MRI Guided Biopsy to Find "Hidden" Prostate Tumors
Scans for diagnosis and staging - MRI-Magnetic Resonance Imaging
Thursday, October 08 2009 18:00
Why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer? Clinical researchers at Princess Margaret Hospital (PMH) in Toronto, Canada believe they can now answer that baffling question.
Monday, October 05 2009 13:09
NSAID Made No Difference to Cancer Growth
To see whether Celebrex (celecoxib) can reduce prostate cancer size and spread, a team from several leading US cancer centers led by Dr. Alan Partin and Dr. Michael Carducci conducted a randomized, double-blind trial enrolling high-risk men before primary treatment with surgery or radiation. They measured the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy on these men.
Last Updated (Wednesday, November 04 2009 10:32) Friday, September 18 2009 06:27
Dr. Gerald Chodak outlines controversy over antiandrogens
Men fighting metastatic prostate cancer may be frustrated to discover that doctors disagree with one another. For example, a lot of controversy surrounds the question of whether to block male hormones from the adrenal gland by use of a drug such as bicalutamide (Casodex). In a video, Dr. Gerald Chodak, a Chicago urologist, discusses how to maximize survival.
PSA Velocity May be Irrelevant in Detection of Prostate Cancer
Diagnosis + Stage - PSA Velocity + Free to Bound PSA
By Friday, September 18 2009 04:18
Measuring velocity of prostate cancer specific antigen rise over time may not be necessary before deciding whether a man needs a prostate biopsy, according to a large new study from urologists at US and European cancer centers.
PSA velocity (PSAV) is a term used for change PSA levels in the blood over time. Instead of basing a decision to recommend biopsy (or not) on a single annual PSA reading, the urologist looks at a series of tests and calculates the rate of rise over time.
The new study suggests that calculating PSA velocity does not help to detect prostate cancer once PSA and age are taken into consideration.This finding was reported by European Association of Urolog this August. "Some guidelines," Scardino notes, "do incorporate PSAV cut points as an indication for biopsy."
First Evidence of Virus Link to Some Prostate Cancers
By Monday, September 07 2009 00:00
A type of virus known to cause leukemia and sarcomas in animals has been found for the first time in human prostate cancer cells, according to researchers at the University of Utah and Columbia University medical schools. Their discovery may help in identifying a viral cause of prostate cancer.This would open opportunities for developing diagnostic tests, vaccines, and therapies for treating the cancer.
The researchers say they found the XMRV virus in almost a third of the prostate tumors they looked at.
"We found that XMRV was present in 27 percent of prostate cancers we examined and that it was associated with more aggressive tumors," said Ila R. Singh, M.D., Ph.D., associate professor of pathology at University of Utah and the study’s senior author. "We still don’t know that this virus causes cancer in people, but that is an important question we’re going to investigate."
More Articles...
Page 2 of 8
